Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

Somatuline Autogel: Acromegaly Self/Partner Injection Study

NCT00149188 ·Status: COMPLETED ·Phase: PHASE4

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398 ·Status: COMPLETED ·Phase: PHASE4

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

NCT00210457 ·Status: COMPLETED ·Phase: PHASE3

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

NCT02493517 ·Status: COMPLETED ·Phase: PHASE3

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

NCT01471405 ·Status: COMPLETED

Non Interventional Post Marketing Programme in Acromegaly

NCT00747500 ·Status: COMPLETED

Somatuline Predictive Factors in Acromegaly and NET

NCT01840449 ·Status: COMPLETED

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

NCT00690898 ·Status: COMPLETED ·Phase: PHASE3

Predictive Factors Study

NCT02020499 ·Status: TERMINATED

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

NCT00145405 ·Status: COMPLETED ·Phase: PHASE4

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

NCT05431803 ·Status: COMPLETED

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

NCT04003519 ·Status: WITHDRAWN

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682 ·Status: COMPLETED ·Phase: PHASE3

Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

NCT02396966 ·Status: COMPLETED

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

NCT01995734 ·Status: APPROVED_FOR_MARKETING

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

NCT06607666 ·Status: COMPLETED

Study in Polish Acromegalic Patients Treated With Somatuline Autogel

NCT01333384 ·Status: COMPLETED

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

NCT01618513 ·Status: COMPLETED ·Phase: PHASE4

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

NCT00088582 ·Status: COMPLETED ·Phase: PHASE2

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

NCT02698384 ·Status: TERMINATED

Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery

NCT00500227 ·Status: COMPLETED